The inhibitory effect of ursodeoxycholic acid and pentoxifylline on platelet derived growth factor-stimulated proliferation is distinct from an effect by cyclic AMP.

scientific article published in June 1998

The inhibitory effect of ursodeoxycholic acid and pentoxifylline on platelet derived growth factor-stimulated proliferation is distinct from an effect by cyclic AMP. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S0162-3109(98)00021-6
P698PubMed publication ID9754904

P2093author name stringT C Peterson
R Isbrucker
G Slysz
P2860cites workA multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study GroupQ28243457
Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliabilityQ29617252
Inhibition of the EGF-Activated MAP Kinase Signaling Pathway by Adenosine 3′,5′-MonophosphateQ30464735
Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacyQ34173602
Platelet-derived growth factor and its role in health and diseaseQ37583401
Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosisQ39514969
Effect of ingested pentoxifylline on neutrophil superoxide anion productionQ40152029
Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategiesQ40911465
In vitro effect of platelet-derived growth factor on fibroproliferation and effect of cytokine antagonistsQ41433205
Membranes and bile formation. Composition of several mammalian biles and their membrane-damaging propertiesQ41543325
Inhibition of fibroproliferation by pentoxifylline. Activity of metabolite-1 and lack of role of adenosine receptorsQ42521668
Inhibition by pentoxifylline of extracellular signal-regulated kinase activation by platelet-derived growth factor in hepatic stellate cellsQ42580701
Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.Q54118475
Cyclic AMP-Independent Inhibition of Voltage-Sensitive Calcium Channels by Forskolin in PC12 CellsQ58214003
Involvement of phosphatidylinositol 3-kinase in the activation of extracellular signal-regulated kinase by PDGF in hepatic stellate cellsQ61763100
Fibroproliferation in liver disease: role of monocyte factorsQ67743304
Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytesQ68019505
Immunomodulatory effects of ursodeoxycholic acid on immune responsesQ68225187
Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patientsQ68496172
The mitogenic effect of platelet-derived growth factor in human hepatic stellate cells requires calcium influxQ71569068
Effect of pentoxifylline in rat and swine models of hepatic fibrosis: role of fibroproliferation in its mechanismQ71663164
A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acidQ72189521
Hepatocyte proliferation in primary biliary cirrhosis as assessed by proliferating cell nuclear antigen and Ki-67 antigen labellingQ72240000
Expression of platelet-derived growth factor in a model of acute liver injuryQ72271873
Phosphodiesterase inhibitory profile of some related xanthine derivatives pharmacologically active on the peripheral microcirculationQ72310404
Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cellsQ73574969
Platelet-derived growth factor and pentoxifylline modulation of collagen synthesis in myofibroblastsQ74345557
P433issue3
P921main subjectpentoxifyllineQ416331
P304page(s)181-191
P577publication date1998-06-01
P1433published inImmunopharmacologyQ24031542
P1476titleThe inhibitory effect of ursodeoxycholic acid and pentoxifylline on platelet derived growth factor-stimulated proliferation is distinct from an effect by cyclic AMP.
P478volume39

Reverse relations

cites work (P2860)
Q34687676Drug therapy of primary biliary diseases: classical and modern strategies.
Q36197335Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.
Q35592380Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.
Q33723536Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases
Q43263224The role of adenosine receptors in the action of theophylline on human peripheral blood mononuclear cells from healthy and asthmatic subjects.
Q51420049Xanthines and Phosphodiesterase Inhibitors.

Search more.